Literature DB >> 11858486

Single cell analysis of factor VIII-specific T cells in hemophilic mice after treatment with human factor VIII.

Maria Sasgary1, Rafi U Ahmad, Hans Peter Schwarz, Peter L Turecek, Birgit M Reipert.   

Abstract

A multi-parameter flow-cytometry assay was established suitable for analyzing T-cell-specific cell surface markers (CD3, CD4) together with intracellular cytokines on a single cell level. This assay was used to identify the frequency and the kinetic of different populations of factor VIII (FVIII)-specific CD4+ T cells in hemophilic E-17 mice after treatment with human FVIII. A clear temporal correlation was found between the appearance of FVIII-specific CD4+ T cells in the spleen and the detection of anti-FVIII antibodies in plasma. These cells and antibodies were detectable in all experiments after two doses of FVIII and in a few even after a single dose. The IFN-gamma-producing T cells were the most prominent type of FVIII-specific T cells suggesting Th1-type T cells have an important role in regulating the anti-FVIII immune response in E-17 mice. IL-10-producing T cells were the second most dominant type. They were detectable after two doses of FVIII and increased in frequency after four. Cytokine co-expression studies analyzing IL-10 and IFN-gamma in the same cell indicated that there might be at least two types of IL-10 positive T cells, those cells that produce IL-10 only and in addition cells that produce IL-10 and IFN-gamma. Furthermore, FVIII-specific T cells producing IL-2 were found in all experiments after two doses of FVIII. In a few experiments IL-4-producing T cells were seen but in most experiments they were not detectable. In contrast, IL-4 could be found in supernatants of in vitro restimulated CD8- spleen cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11858486

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice.

Authors:  Vivek S Purohit; C Russell Middaugh; Sathyamangalam V Balasubramanian
Journal:  J Pharm Sci       Date:  2006-02       Impact factor: 3.534

2.  Maternally transferred anti-factor VIII IgG reduce the anti-factor VIII humoral immune response in factor VIII-deficient mice.

Authors:  Yann Meslier; Sébastien André; Maud Teyssandier; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Immunology       Date:  2010-12       Impact factor: 7.397

3.  CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice.

Authors:  Katharina N Steinitz; Pauline M van Helden; Brigitte Binder; David C Wraith; Sabine Unterthurner; Corinna Hermann; Maria Schuster; Rafi U Ahmad; Markus Weiller; Christian Lubich; Maurus de la Rosa; Hans Peter Schwarz; Birgit M Reipert
Journal:  Blood       Date:  2012-03-06       Impact factor: 22.113

4.  High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors.

Authors:  Christina Hausl; Rafi U Ahmad; Maria Sasgary; Christopher B Doering; Pete Lollar; Günter Richter; Hans Peter Schwarz; Peter L Turecek; Birgit M Reipert
Journal:  Blood       Date:  2005-08-09       Impact factor: 22.113

5.  Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application.

Authors:  Paul E Monahan; Clinton D Lothrop; Junjiang Sun; Matthew L Hirsch; Tal Kafri; Boris Kantor; Rita Sarkar; D Michael Tillson; Joseph R Elia; R Jude Samulski
Journal:  Mol Ther       Date:  2010-08-10       Impact factor: 11.454

6.  The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice.

Authors:  John F Healey; Ernest T Parker; Rachel T Barrow; Travis J Langley; William R Church; Pete Lollar
Journal:  Thromb Haemost       Date:  2009-07       Impact factor: 5.249

7.  Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.

Authors:  Christopher B Doering; Gabriela Denning; Jordan E Shields; Eli J Fine; Ernest T Parker; Alok Srivastava; Pete Lollar; H Trent Spencer
Journal:  Hum Gene Ther       Date:  2018-10       Impact factor: 5.695

Review 8.  A cellular viewpoint of anti-FVIII immune response in hemophilia A.

Authors:  Sebastien André; Yann Meslier; Jordan D Dimitrov; Yohann Repessé; Srinivas V Kaveri; Sebastien Lacroix-Desmazes; Suryasarathi Dasgupta
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.